Royalty Pharma (RPRX) Non Operating Income (2019 - 2026)

Royalty Pharma has reported Non Operating Income for 8 years, with the latest figure at -$94.8 million in Q1 2026.

• Quarterly Non Operating Income rose 4.98% year-over-year to -$94.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$229.4 million (down 75.24% YoY) and the FY2025 annual result came in at -$235.3 million, down 713.32% from the prior year.
• Non Operating Income fell to -$94.8 million in Q1 2026 per RPRX's latest filing, from -$32.5 million in the prior quarter.
• Over five years, Non Operating Income peaked at $113.8 million in Q2 2022 and troughed at -$127.4 million in Q4 2022.
• A 5-year average of -$9.4 million and a median of -$27.2 million in 2024 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Non Operating Income soared 342.75% in 2024, then plunged 243.52% in 2025.
• Over 5 years, Non Operating Income stood at -$127.4 million in 2022, then jumped by 182.19% to $104.7 million in 2023, then slumped by 125.95% to -$27.2 million in 2024, then decreased by 19.53% to -$32.5 million in 2025, then sank by 191.92% to -$94.8 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$94.8 million, -$32.5 million, and $17.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.